Back to News
Market Impact: 0.2
Agomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's Disease
Source: Nasdaq
Healthcare & Biotech
AgomAb Therapeutics said the first patient has been dosed in NOV-ERA, a global Phase 2b trial of ontunisertib in patients with symptomatic fibrostenosing Crohn's disease. The announcement marks trial enrollment progress but provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
AGMB0.55
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Top biotechnology stock pick from Guggenheim
- Needham raises Starling Oncology stock price target on growth outlook
- Stifel raises IQVIA stock price target on improving market backdrop